Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital
Background The increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have investigated the possible relationship between outpatient fluoroquinolone consumption and resistance in hospital. Objective To investigate the relati...
Saved in:
Published in | Journal of antimicrobial chemotherapy Vol. 65; no. 12; pp. 2650 - 2657 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Oxford University Press
01.12.2010
Oxford Publishing Limited (England) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background The increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have investigated the possible relationship between outpatient fluoroquinolone consumption and resistance in hospital. Objective To investigate the relationship between inpatient and outpatient fluoroquinolone use and ciprofloxacin-resistant E. coli in a teaching hospital. Methods An ecological study was conducted in Toulouse University Hospital and its surrounding area, the Midi-Pyrénées region (south-western France), in 2004–07. Dynamic regression models were built to study how the hospital resistance rate was linearly related to current and past values of fluoroquinolone consumption. Resistance forecasts for 2008 were then calculated and compared with actual rates for the first 5 months of the year. Results Mean resistance rate was 13.7% and mean fluoroquinolone use was 89.9 defined daily doses (DDDs)/1000 inpatient days in hospital and 2.6 DDDs/1000 inhabitants/day in the region. Taking into account past values of fluoroquinolone consumption in hospital and in outpatients, only levofloxacin use in the community remained significantly associated with resistance in hospital, with a lag of 12 months. This model explained 50% of the resistance variability. Conclusions This ecological analysis, conducted on a teaching hospital scale, suggests that ciprofloxacin resistance in E. coli in hospital is linked to consumption of fluoroquinolones within the hospital and its surrounding community. Among all fluoroquinolones, levofloxacin use was found to be the most important factor. Consumption in outpatients appears to be a relevant determinant to consider in designing interventions to reduce resistance in hospitals. |
---|---|
AbstractList | BACKGROUNDThe increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have investigated the possible relationship between outpatient fluoroquinolone consumption and resistance in hospital.OBJECTIVETo investigate the relationship between inpatient and outpatient fluoroquinolone use and ciprofloxacin-resistant E. coli in a teaching hospital.METHODSAn ecological study was conducted in Toulouse University Hospital and its surrounding area, the Midi-Pyrénées region (south-western France), in 2004-07. Dynamic regression models were built to study how the hospital resistance rate was linearly related to current and past values of fluoroquinolone consumption. Resistance forecasts for 2008 were then calculated and compared with actual rates for the first 5 months of the year.RESULTSMean resistance rate was 13.7% and mean fluoroquinolone use was 89.9 defined daily doses (DDDs)/1000 inpatient days in hospital and 2.6 DDDs/1000 inhabitants/day in the region. Taking into account past values of fluoroquinolone consumption in hospital and in outpatients, only levofloxacin use in the community remained significantly associated with resistance in hospital, with a lag of 12 months. This model explained 50% of the resistance variability.CONCLUSIONSThis ecological analysis, conducted on a teaching hospital scale, suggests that ciprofloxacin resistance in E. coli in hospital is linked to consumption of fluoroquinolones within the hospital and its surrounding community. Among all fluoroquinolones, levofloxacin use was found to be the most important factor. Consumption in outpatients appears to be a relevant determinant to consider in designing interventions to reduce resistance in hospitals. Background The increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have investigated the possible relationship between outpatient fluoroquinolone consumption and resistance in hospital. Objective To investigate the relationship between inpatient and outpatient fluoroquinolone use and ciprofloxacin-resistant E. coli in a teaching hospital. Methods An ecological study was conducted in Toulouse University Hospital and its surrounding area, the Midi-Pyrénées region (south-western France), in 2004–07. Dynamic regression models were built to study how the hospital resistance rate was linearly related to current and past values of fluoroquinolone consumption. Resistance forecasts for 2008 were then calculated and compared with actual rates for the first 5 months of the year. Results Mean resistance rate was 13.7% and mean fluoroquinolone use was 89.9 defined daily doses (DDDs)/1000 inpatient days in hospital and 2.6 DDDs/1000 inhabitants/day in the region. Taking into account past values of fluoroquinolone consumption in hospital and in outpatients, only levofloxacin use in the community remained significantly associated with resistance in hospital, with a lag of 12 months. This model explained 50% of the resistance variability. Conclusions This ecological analysis, conducted on a teaching hospital scale, suggests that ciprofloxacin resistance in E. coli in hospital is linked to consumption of fluoroquinolones within the hospital and its surrounding community. Among all fluoroquinolones, levofloxacin use was found to be the most important factor. Consumption in outpatients appears to be a relevant determinant to consider in designing interventions to reduce resistance in hospitals. The increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have investigated the possible relationship between outpatient fluoroquinolone consumption and resistance in hospital. o investigate the relationship between inpatient and outpatient fluoroquinolone use and ciprofloxacin-resistant E. coli in a teaching hospital. An ecological study was conducted in Toulouse University Hospital and its surrounding area, the Midi-Pyrenees region (south-western France), in 2004-07. Dynamic regression models were built to study how the hospital resistance rate was linearly related to current and past values of fluoroquinolone consumption. Resistance forecasts for 2008 were then calculated and compared with actual rates for the first 5 months of the year. Mean resistance rate was 13.7% and mean fluoroquinolone use was 89.9 defined daily doses (DDDs)/1000 inpatient days in hospital and 2.6 DDDs/1000 inhabitants/day in the region. Taking into account past values of fluoroquinolone consumption in hospital and in outpatients, only levofloxacin use in the community remained significantly associated with resistance in hospital, with a lag of 12 months. This model explained 50% of the resistance variability. This ecological analysis, conducted on a teaching hospital scale, suggests that ciprofloxacin resistance in E. coli in hospital is linked to consumption of fluoroquinolones within the hospital and its surrounding community. Among all fluoroquinolones, levofloxacin use was found to be the most important factor. Consumption in outpatients appears to be a relevant determinant to consider in designing interventions to reduce resistance in hospitals. The increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have investigated the possible relationship between outpatient fluoroquinolone consumption and resistance in hospital. To investigate the relationship between inpatient and outpatient fluoroquinolone use and ciprofloxacin-resistant E. coli in a teaching hospital. An ecological study was conducted in Toulouse University Hospital and its surrounding area, the Midi-Pyrénées region (south-western France), in 2004-07. Dynamic regression models were built to study how the hospital resistance rate was linearly related to current and past values of fluoroquinolone consumption. Resistance forecasts for 2008 were then calculated and compared with actual rates for the first 5 months of the year. Mean resistance rate was 13.7% and mean fluoroquinolone use was 89.9 defined daily doses (DDDs)/1000 inpatient days in hospital and 2.6 DDDs/1000 inhabitants/day in the region. Taking into account past values of fluoroquinolone consumption in hospital and in outpatients, only levofloxacin use in the community remained significantly associated with resistance in hospital, with a lag of 12 months. This model explained 50% of the resistance variability. This ecological analysis, conducted on a teaching hospital scale, suggests that ciprofloxacin resistance in E. coli in hospital is linked to consumption of fluoroquinolones within the hospital and its surrounding community. Among all fluoroquinolones, levofloxacin use was found to be the most important factor. Consumption in outpatients appears to be a relevant determinant to consider in designing interventions to reduce resistance in hospitals. Background The increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have investigated the possible relationship between outpatient fluoroquinolone consumption and resistance in hospital. Objective To investigate the relationship between inpatient and outpatient fluoroquinolone use and ciprofloxacin-resistant E. coli in a teaching hospital. Methods An ecological study was conducted in Toulouse University Hospital and its surrounding area, the Midi-Pyrenees region (south-western France), in 2004-07. Dynamic regression models were built to study how the hospital resistance rate was linearly related to current and past values of fluoroquinolone consumption. Resistance forecasts for 2008 were then calculated and compared with actual rates for the first 5 months of the year. Results Mean resistance rate was 13.7% and mean fluoroquinolone use was 89.9 defined daily doses (DDDs)/1000 inpatient days in hospital and 2.6 DDDs/1000 inhabitants/day in the region. Taking into account past values of fluoroquinolone consumption in hospital and in outpatients, only levofloxacin use in the community remained significantly associated with resistance in hospital, with a lag of 12 months. This model explained 50% of the resistance variability. Conclusions This ecological analysis, conducted on a teaching hospital scale, suggests that ciprofloxacin resistance in E. coli in hospital is linked to consumption of fluoroquinolones within the hospital and its surrounding community. Among all fluoroquinolones, levofloxacin use was found to be the most important factor. Consumption in outpatients appears to be a relevant determinant to consider in designing interventions to reduce resistance in hospitals. |
Author | Degris, E. Gallini, A. Montastruc, J.-L. Archambaud, M. Bourrel, R. Lapeyre-Mestre, M. Desplas, M. Sommet, A. |
Author_xml | – sequence: 1 givenname: A. surname: Gallini fullname: Gallini, A. email: adeline.gallini@gmail.com, Corresponding author. Tel: +33-5-61-25-51-12; Fax: +33-5-61-25-51-16; adeline.gallini@gmail.com organization: Université de Toulouse, Université Paul Sabatier, Unité de Pharmacoépidémiologie EA3696, Faculté de Médecine, 37 Allées Jules Guesde, F-31000 Toulouse, France – sequence: 2 givenname: E. surname: Degris fullname: Degris, E. organization: Pharmacie, Centre Hospitalier Universitaire, Toulouse, France – sequence: 3 givenname: M. surname: Desplas fullname: Desplas, M. organization: Pharmacie, Centre Hospitalier Universitaire, Toulouse, France – sequence: 4 givenname: R. surname: Bourrel fullname: Bourrel, R. organization: Échelon régional du service médical Midi-Pyrénées, Caisse nationale d'assurance maladie des travailleurs salariés CNAMTS, Toulouse, France – sequence: 5 givenname: M. surname: Archambaud fullname: Archambaud, M. organization: Laboratoire de Bactériologie et Hygiène, Centre Hospitalier Universitaire, Toulouse, France – sequence: 6 givenname: J.-L. surname: Montastruc fullname: Montastruc, J.-L. organization: Université de Toulouse, Université Paul Sabatier, Unité de Pharmacoépidémiologie EA3696, Faculté de Médecine, 37 Allées Jules Guesde, F-31000 Toulouse, France – sequence: 7 givenname: M. surname: Lapeyre-Mestre fullname: Lapeyre-Mestre, M. organization: Université de Toulouse, Université Paul Sabatier, Unité de Pharmacoépidémiologie EA3696, Faculté de Médecine, 37 Allées Jules Guesde, F-31000 Toulouse, France – sequence: 8 givenname: A. surname: Sommet fullname: Sommet, A. organization: Université de Toulouse, Université Paul Sabatier, Unité de Pharmacoépidémiologie EA3696, Faculté de Médecine, 37 Allées Jules Guesde, F-31000 Toulouse, France |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23475113$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20876240$$D View this record in MEDLINE/PubMed |
BookMark | eNqF0c9qFDEABvAgFbutXnwACYIIwtj8z8yx1GqLFS8VZS8hm0nYbGeTaZKR9hl8aTPsuoIXIZCE_PiS8J2AoxCDBeAlRu8x6ujZRpuz_u6ecvwELDATqCGow0dggSjijWScHoOTnDcIIcFF-wwcE9RKQRhagF_XwQ2TDcbC6GBdxhTvJx_iUO-AJoY8bcfiY4B-HqMu3oaSoQ49jFM57CswfkzRDfFBGx-aZLPPRYcCL7NZ2-TN2usaOPg5ScMp-J82ZV8e4Trm0Rc9PAdPnR6yfbGfT8G3j5e3F1fNzddP1xfnN41hsisNa-2KYII4c8YgTIi0WGjOCOuJ05oJyyWSPcHcEIq7Tq6sk8x0vSAOIcboKXi7yx3nv9pc1NZnY4dBBxunrDpEqGSdJP-VUlAmKZGyytf_yE2cUqjfUC3mXUskmePe7ZBJMedknRqT3-r0qDBSc5WqVql2VVb8ap84rba2P9A_3VXwZg90NnpwSQfj819Xn8YxptU1O1f7sA-Hc53ulJBUcnX1Y6k-0OV3vvxyqz7T3whtuus |
CODEN | JACHDX |
CitedBy_id | crossref_primary_10_1038_s43856_023_00275_z crossref_primary_10_1590_1519_6984_269778 crossref_primary_10_1186_s12889_019_6804_3 crossref_primary_10_1093_aje_kws273 crossref_primary_10_1016_j_jmii_2011_12_019 crossref_primary_10_1007_s10096_012_1640_8 crossref_primary_10_1093_jac_dkq525 crossref_primary_10_1016_j_amjmed_2012_10_027 crossref_primary_10_1590_1519_6984_231838 crossref_primary_10_4236_abb_2013_44066 crossref_primary_10_1093_jac_dkaa165 crossref_primary_10_2903_j_efsa_2017_4872 crossref_primary_10_1016_j_therap_2017_03_002 crossref_primary_10_1093_jac_dks330 crossref_primary_10_1177_0300060517703573 crossref_primary_10_3947_ic_2014_46_4_226 crossref_primary_10_1093_jac_dkq471 crossref_primary_10_5812_archcid_18690 crossref_primary_10_1093_aje_kwz239 crossref_primary_10_17795_ajcmi_39785 crossref_primary_10_1128_AAC_01908_13 crossref_primary_10_1016_j_ajic_2014_12_010 crossref_primary_10_1016_j_ijantimicag_2023_106768 crossref_primary_10_1093_cid_cir449 crossref_primary_10_2903_j_efsa_2024_8589 crossref_primary_10_1007_s15010_019_01305_6 crossref_primary_10_1155_2014_537681 crossref_primary_10_1093_cid_cix765 crossref_primary_10_1016_j_ijid_2012_10_005 crossref_primary_10_1111_j_1365_2125_2011_04161_x crossref_primary_10_3402_jchimp_v1i2_7209 crossref_primary_10_1007_s10096_015_2417_7 crossref_primary_10_1017_ice_2018_245 crossref_primary_10_1093_cid_cis509 crossref_primary_10_1017_ice_2015_41 crossref_primary_10_1007_s10096_014_2264_y crossref_primary_10_1186_s12879_020_04981_0 crossref_primary_10_1017_ice_2016_315 crossref_primary_10_5812_jjm_100348 crossref_primary_10_1016_j_ijid_2015_01_006 crossref_primary_10_1093_jacamr_dlad001 crossref_primary_10_1371_journal_pone_0219190 |
Cites_doi | 10.1001/archinte.160.2.159 10.1371/journal.pmed.1000084 10.1128/AAC.00856-08 10.1016/S0924-8579(99)00135-1 10.1016/S0732-8893(97)00216-2 10.1016/j.medmal.2005.06.007 10.1086/598632 10.1086/322667 10.1016/S1473-3099(06)70599-0 10.1086/514747 10.1086/432056 10.2307/30141993 10.1046/j.1469-0691.2001.00071.x 10.1086/379709 10.1016/S0399-077X(05)81383-6 10.1093/jac/dkl183 10.3201/eid1305.061293 10.1093/jac/dkl147 10.1086/345754 10.1086/381549 10.1128/AAC.39.2.520 10.1086/322677 10.1093/ije/18.1.269 10.1128/AAC.43.11.2736 10.3201/eid1411.070467 10.1016/S0140-6736(05)17907-0 10.1093/jac/dkh510 10.1093/jac/47.4.502 10.1111/j.1469-0691.2005.01098.x 10.1093/jac/46.2.223 10.1128/AAC.48.6.1934-1940.2004 10.1001/jama.289.7.885 10.1002/pds.1110 10.1128/AAC.45.11.3084-3091.2001 |
ContentType | Journal Article |
Copyright | 2015 INIST-CNRS Copyright Oxford Publishing Limited(England) Dec 2010 |
Copyright_xml | – notice: 2015 INIST-CNRS – notice: Copyright Oxford Publishing Limited(England) Dec 2010 |
DBID | BSCLL IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7QO 7T7 7U7 7U9 8FD C1K FR3 H94 K9. M7N NAPCQ P64 7X8 |
DOI | 10.1093/jac/dkq351 |
DatabaseName | Istex Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Toxicology Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Virology and AIDS Abstracts Technology Research Database Toxicology Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management Nursing & Allied Health Premium Biotechnology Research Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Virology and AIDS Abstracts MEDLINE Engineering Research Database |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1460-2091 |
EndPage | 2657 |
ExternalDocumentID | 2205249461 10_1093_jac_dkq351 20876240 23475113 ark_67375_HXZ_D3ZW5ZMT_K |
Genre | Journal Article Feature |
GeographicLocations | France Toulouse France |
GeographicLocations_xml | – name: France – name: Toulouse France |
GroupedDBID | --- -E4 .2P .GJ .I3 .XZ .ZR 0R~ 18M 1TH 29J 2WC 3O- 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 6.Y 70D AABJS AABMN AABZA AACZT AAESY AAIYJ AAJKP AAJQQ AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AARHZ AASNB AAUQX AAVAP AAWDT AAWTL ABEUO ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABPTD ABQLI ABQTQ ABSAR ABSMQ ABWST ABXVV ABZBJ ACCCW ACFRR ACGFO ACGFS ACIMA ACIWK ACMRT ACPQN ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEIU ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADORX ADQLU ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEJOX AEKPW AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFZL AFIYH AFOFC AFRAH AFXAL AFXEN AFYAG AGINJ AGKEF AGKRT AGQXC AGSYK AGUTN AHMBA AHXPO AI. AIAGR AIJHB AIKOY AIMBJ AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APJGH APWMN AQDSO AQKUS ASMCH ASPBG ATTQO AVNTJ AVWKF AWCFO AXUDD AZFZN AZQFJ BAWUL BAYMD BCRHZ BEYMZ BGYMP BHONS BSCLL BTRTY BVRKM BYORX BZKNY C45 CAG CASEJ CDBKE COF CS3 CZ4 DAKXR DIK DILTD DPORF DPPUQ DU5 D~K E3Z EBS ECGQY EE~ EIHJH EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H5~ HAR HH5 HVGLF HW0 HZ~ IOX J21 J5H JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z M49 MBLQV MHKGH ML0 N9A NGC NOMLY NOYVH NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OBS OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD R44 RD5 RHF RNI ROL ROX ROZ RUSNO RW1 RXO RZF RZO TCURE TEORI TJX TMA TR2 UCJ VH1 W8F WOQ X7H Y6R YAYTL YKOAZ YXANX ZGI ZKX ZXP ~91 ~A~ AANRK ABPTK ALXQX H13 IQODW OBFPC AAUAY ABQNK ACZBC ADQBN AEHUL AFSHK AGMDO ATGXG CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7QO 7T7 7U7 7U9 8FD C1K FR3 H94 K9. M7N NAPCQ P64 7X8 |
ID | FETCH-LOGICAL-c479t-48eb212054fcc01227e16a5424d2faa46e5707d215c231997bef74c9d62f00443 |
ISSN | 0305-7453 |
IngestDate | Fri Aug 16 09:58:34 EDT 2024 Sat Oct 05 05:30:05 EDT 2024 Thu Oct 10 22:13:05 EDT 2024 Thu Sep 12 16:30:15 EDT 2024 Tue Oct 15 23:37:29 EDT 2024 Sun Oct 22 16:09:11 EDT 2023 Sun Mar 31 11:38:32 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | Consumption Human Drug Escherichia coli dynamic regression Time series Regression antimicrobials Antimicrobial agent Resistance Fluoroquinolone derivatives University Dynamics linear transfer function Bacteria drug use Ambulatory Hospital Antibacterial agent Time analysis Enterobacteriaceae time-series analysis |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c479t-48eb212054fcc01227e16a5424d2faa46e5707d215c231997bef74c9d62f00443 |
Notes | href:dkq351.pdf ArticleID:dkq351 ark:/67375/HXZ-D3ZW5ZMT-K istex:CBDBB7D82E3E1EA0822CD8AB237EDFE8607D02E5 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
PMID | 20876240 |
PQID | 815982722 |
PQPubID | 32192 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_902374972 proquest_miscellaneous_763473277 proquest_journals_815982722 crossref_primary_10_1093_jac_dkq351 pubmed_primary_20876240 pascalfrancis_primary_23475113 istex_primary_ark_67375_HXZ_D3ZW5ZMT_K |
PublicationCentury | 2000 |
PublicationDate | 2010-12-01 |
PublicationDateYYYYMMDD | 2010-12-01 |
PublicationDate_xml | – month: 12 year: 2010 text: 2010-12-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Oxford |
PublicationPlace_xml | – name: Oxford – name: England |
PublicationTitle | Journal of antimicrobial chemotherapy |
PublicationTitleAlternate | J Antimicrob Chemother |
PublicationYear | 2010 |
Publisher | Oxford University Press Oxford Publishing Limited (England) |
Publisher_xml | – name: Oxford University Press – name: Oxford Publishing Limited (England) |
References | Garau (4_6350302) 1999; 43 Neu (1_14139202) 1987; 82 Goossens (9_18679314) 2005; 365 McDonald (39_11357816) 2001; 45 Lie (14_32502807) 2008; 14 Harris (8_10379196) 2000; 133 Harrison (6_19333161) 2005; 35 Nurminen (33_16170239) 1995; 48 L pez-Lozano (20_6512429) 2000; 14 Sabuncu (25_34998955) 2009; 6 (41_38258483) -1; -1 Bolon (7_18191712) 2004; 48 (22_31051521) 2001; 7 (23_38186834) 2005; 35 Robicsek (2_22729867) 2006; 6 (31_22099948) 2006; 58 Gimber (36_5926074) 1998; 19 (12_18663278) 2005; 55 (15_38258676) -1; -1 Lepelletier (37_11003661) 1999; 29 Pena (38_15849953) 1995; 39 Neuhauser (13_17504045) 2003; 289 Mahamat (21_18729915) 2005; 11 (11_38310011) -1; -1 (32_22198970) 2006; 58 Lautenbach (3_18057887) 2004; 38 Ena (35_5969279) 1998; 30 Poirel (40_29950338) 2007; 13 (10_38222752) -1; -1 (24_32979525) 2009; 53 Friedrich (17_10929826) 1999; 28 GREENLAND (34_5259060) 1989; 18 Goettsch (18_10426267) 2000; 46 Urb nek (19_19453590) 2005; 14 Cizman (16_11085082) 2001; 47 (5_38268326) -1; -1 |
References_xml | – volume: 133 start-page: 159 issn: 0003-4819 issue: 2 year: 2000 ident: 8_10379196 publication-title: Annals of Internal Medicine doi: 10.1001/archinte.160.2.159 contributor: fullname: Harris – volume: 6 start-page: e1000084 issn: 1549-1277 issue: 6 year: 2009 ident: 25_34998955 doi: 10.1371/journal.pmed.1000084 contributor: fullname: Sabuncu – volume: 53 start-page: 912 issn: 0066-4804 issue: 3 year: 2009 ident: 24_32979525 publication-title: Antimicrobial Agents and Chemotherapy doi: 10.1128/AAC.00856-08 – volume: 14 start-page: 21 issn: 0924-8579 issue: 1 year: 2000 ident: 20_6512429 publication-title: International journal of antimicrobial agents doi: 10.1016/S0924-8579(99)00135-1 contributor: fullname: L pez-Lozano – volume: 30 start-page: 103 issn: 0732-8893 issue: 2 year: 1998 ident: 35_5969279 publication-title: Diagnostic microbiology and infectious disease doi: 10.1016/S0732-8893(97)00216-2 contributor: fullname: Ena – volume: 35 start-page: 543 issn: 0399-077X issue: 11 year: 2005 ident: 6_19333161 publication-title: M decine et maladies infectieuses doi: 10.1016/j.medmal.2005.06.007 contributor: fullname: Harrison – volume: 29 start-page: 548 issn: 1058-4838 issue: 3 year: 1999 ident: 37_11003661 publication-title: Clinical Infectious Diseases doi: 10.1086/598632 contributor: fullname: Lepelletier – volume: -1 start-page: MASTER issn: 1058-4838 year: -1 ident: 41_38258483 publication-title: Clinical Infectious Diseases doi: 10.1086/322667 – volume: 6 start-page: 629 issn: 1473-3099 issue: 10 year: 2006 ident: 2_22729867 publication-title: The Lancet infectious diseases doi: 10.1016/S1473-3099(06)70599-0 contributor: fullname: Robicsek – volume: 28 start-page: 1017 issn: 1058-4838 issue: 5 year: 1999 ident: 17_10929826 publication-title: Clinical Infectious Diseases doi: 10.1086/514747 contributor: fullname: Friedrich – volume: -1 start-page: MASTER issn: 1058-4838 year: -1 ident: 10_38222752 publication-title: Clinical Infectious Diseases doi: 10.1086/432056 – volume: 19 start-page: 85 issn: 0899-823X issue: 2 year: 1998 ident: 36_5926074 publication-title: Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America doi: 10.2307/30141993 contributor: fullname: Gimber – volume: 7 start-page: 29 issn: 1198-743X year: 2001 ident: 22_31051521 publication-title: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases doi: 10.1046/j.1469-0691.2001.00071.x – volume: -1 start-page: MASTER issn: 1058-4838 year: -1 ident: 11_38310011 publication-title: Clinical Infectious Diseases doi: 10.1086/379709 – volume: 35 start-page: S127 issn: 0399-077X year: 2005 ident: 23_38186834 publication-title: M decine et maladies infectieuses doi: 10.1016/S0399-077X(05)81383-6 – volume: 58 start-page: 423 issn: 0305-7453 issue: 2 year: 2006 ident: 32_22198970 publication-title: Journal of Antimicrobial Chemotherapy doi: 10.1093/jac/dkl183 – volume: 13 start-page: 803 issn: 1080-6040 issue: 5 year: 2007 ident: 40_29950338 publication-title: Emerging infectious diseases doi: 10.3201/eid1305.061293 contributor: fullname: Poirel – volume: 58 start-page: 159 issn: 0305-7453 issue: 1 year: 2006 ident: 31_22099948 publication-title: Journal of Antimicrobial Chemotherapy doi: 10.1093/jac/dkl147 – volume: -1 start-page: MASTER issn: 1058-4838 year: -1 ident: 5_38268326 publication-title: Clinical Infectious Diseases doi: 10.1086/345754 – volume: 38 start-page: 655 issn: 1058-4838 issue: 5 year: 2004 ident: 3_18057887 publication-title: Clinical Infectious Diseases doi: 10.1086/381549 contributor: fullname: Lautenbach – volume: 39 start-page: 520 issn: 0066-4804 issue: 2 year: 1995 ident: 38_15849953 publication-title: Antimicrobial Agents and Chemotherapy doi: 10.1128/AAC.39.2.520 contributor: fullname: Pena – volume: -1 start-page: MASTER issn: 1058-4838 year: -1 ident: 15_38258676 publication-title: Clinical Infectious Diseases doi: 10.1086/322677 – volume: 18 start-page: 269 issn: 0300-5771 issue: 1 year: 1989 ident: 34_5259060 publication-title: International Journal of Epidemiology doi: 10.1093/ije/18.1.269 contributor: fullname: GREENLAND – volume: 43 start-page: 2736 issn: 0066-4804 issue: 11 year: 1999 ident: 4_6350302 publication-title: Antimicrobial Agents and Chemotherapy doi: 10.1128/AAC.43.11.2736 contributor: fullname: Garau – volume: 14 start-page: 1722 issn: 1080-6040 issue: 11 year: 2008 ident: 14_32502807 publication-title: Emerging infectious diseases doi: 10.3201/eid1411.070467 contributor: fullname: Lie – volume: 82 start-page: 395 issn: 0002-9343 issue: 4A year: 1987 ident: 1_14139202 publication-title: The American journal of medicine contributor: fullname: Neu – volume: 365 start-page: 579 issn: 0140-6736 issue: 9459 year: 2005 ident: 9_18679314 publication-title: Lancet doi: 10.1016/S0140-6736(05)17907-0 contributor: fullname: Goossens – volume: 55 start-page: 57 issn: 0305-7453 issue: 1 year: 2005 ident: 12_18663278 publication-title: Journal of Antimicrobial Chemotherapy doi: 10.1093/jac/dkh510 – volume: 47 start-page: 502 issn: 0305-7453 issue: 4 year: 2001 ident: 16_11085082 publication-title: Journal of Antimicrobial Chemotherapy doi: 10.1093/jac/47.4.502 contributor: fullname: Cizman – volume: 11 start-page: 301 issn: 1198-743X issue: 4 year: 2005 ident: 21_18729915 publication-title: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases doi: 10.1111/j.1469-0691.2005.01098.x contributor: fullname: Mahamat – volume: 46 start-page: 223 issn: 0305-7453 issue: 2 year: 2000 ident: 18_10426267 publication-title: Journal of Antimicrobial Chemotherapy doi: 10.1093/jac/46.2.223 contributor: fullname: Goettsch – volume: 48 start-page: 78 issn: 0379-8070 issue: 2 year: 1995 ident: 33_16170239 publication-title: World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales contributor: fullname: Nurminen – volume: 48 start-page: 1934 issn: 0066-4804 issue: 6 year: 2004 ident: 7_18191712 publication-title: Antimicrobial Agents and Chemotherapy doi: 10.1128/AAC.48.6.1934-1940.2004 contributor: fullname: Bolon – volume: 289 start-page: 885 issn: 0098-7484 issue: 7 year: 2003 ident: 13_17504045 publication-title: JAMA doi: 10.1001/jama.289.7.885 contributor: fullname: Neuhauser – volume: 14 start-page: 741 issn: 1053-8569 issue: 10 year: 2005 ident: 19_19453590 publication-title: Pharmacoepidemiology and drug safety doi: 10.1002/pds.1110 contributor: fullname: Urb nek – volume: 45 start-page: 3084 issn: 0066-4804 issue: 11 year: 2001 ident: 39_11357816 publication-title: Antimicrobial Agents and Chemotherapy doi: 10.1128/AAC.45.11.3084-3091.2001 contributor: fullname: McDonald |
SSID | ssj0006568 |
Score | 2.24081 |
Snippet | Background The increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have... The increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have investigated the... BACKGROUNDThe increase in fluoroquinolone-resistant Escherichia coli has raised the issue of treatment failure in common infections. Few studies have... |
SourceID | proquest crossref pubmed pascalfrancis istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 2650 |
SubjectTerms | Anti-Infective Agents - pharmacology Anti-Infective Agents - therapeutic use Antibiotics Antibiotics. Antiinfectious agents. Antiparasitic agents antimicrobials Biological and medical sciences Chemotherapy Ciprofloxacin - pharmacology Drug resistance Drug Resistance, Bacterial drug use Drug Utilization - statistics & numerical data dynamic regression E coli Escherichia coli Escherichia coli - drug effects Escherichia coli - isolation & purification Escherichia coli Infections - drug therapy Escherichia coli Infections - microbiology Fluoroquinolones - pharmacology Fluoroquinolones - therapeutic use France Hospitals, University Humans Inpatients linear transfer function Medical sciences Microbial Sensitivity Tests Outpatients Pharmacology. Drug treatments resistance time-series analysis |
Title | Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital |
URI | https://api.istex.fr/ark:/67375/HXZ-D3ZW5ZMT-K/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/20876240 https://www.proquest.com/docview/815982722 https://search.proquest.com/docview/763473277 https://search.proquest.com/docview/902374972 |
Volume | 65 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKJiFeEIxbGUyWQH3ZsrWJE8ePgxZaaMfUtaLqS-Qktha2pWNNpY2_wJ_mOM51rOIiVVGTuk6i8-X42PnOdxB6C0EFh5FGGn4oYYLSaQcGd0NqhJzagexIR7oqOXl05PSn5NPMnjUaVYXgVeLvBz_uzCv5H6vCMbCrypL9B8sWncIB-A72hS1YGLZ_ZeNBXmFEhXzwdaHcfKRWyuOUhA7XcpmTGaM4k1DVosyLVVLsQ4MgUsW7zxfXPIhiA6bgKqyMk93eUhk1UoRo6PA8Uj3x3VXJ5jjN6o6sCXKhj-giSsWelBDJqbjIMr5KEunhcDg4GtSWVbu9j-PBSS1PottTLJeT2vrtuy_T8bg3LGmP2erFb0yQNVmRFScI_sigRAsK7wvtpInTBhzoKl-5F9cVJ3K0mlWf7Ghp22x8h11659ihdbW-8QC24dl3KxPCrUl03xo6C0KjaREKoat1D22alNmp3HC_nIc5OiezuJlcJ5dZB3C-A322WmS0qR7ya8XU5Ut4WKWusrJ-GpSGQ5NH6GFmYnyoQfkYNUS8he6PMqbGFmoda030mz08KVP8lnu4hY9LtfSbJ-hnAWK8kPgWiHEFxDhSnxy0GECMKyDG0GANiHEFxFiBWPXEcQlinIP4KZp-6E3e942sQogREMoSg7jCh9gLph0yCNRLYio6DreJSUJTck4cYdM2DSGsDWAewxj1haQkYKFjSkVlsJ6hjRju5gXCjIWu5YS2L-A4czkTDMa2kEtT0ra0RBO9ya3jXWohGE8TOCwPbOhpGzZRKzVc0YRfnSnqJLW9_mzuda35V3s-mnifm2inZtniDzmSmmg7N7WXuZyl53aU3iY1zSbCxa8wHqiXfDwWi9XSg3iBUMukdH0TBnE6JYxCL881hsqzK4VKCPJf_unyttGD8nF-hTaSq5V4DeF54u-k0P8F4zbvug |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | ABC ChemistRy |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Influence+of+fluoroquinolone+consumption+in+inpatients+and+outpatients+on+ciprofloxacin-resistant+Escherichia+coli+in+a+university+hospital&rft.jtitle=Journal+of+antimicrobial+chemotherapy&rft.au=GALLINI%2C+A&rft.au=DEGRIS%2C+E&rft.au=DESPLAS%2C+M&rft.au=BOURREL%2C+R&rft.date=2010-12-01&rft.pub=Oxford+University+Press&rft.issn=0305-7453&rft.eissn=1460-2091&rft.volume=65&rft.issue=12&rft.spage=2650&rft.epage=2657&rft_id=info:doi/10.1093%2Fjac%2Fdkq351&rft.externalDBID=n%2Fa&rft.externalDocID=23475113 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-7453&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-7453&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-7453&client=summon |